Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone

Autor: Kai Sun, Guanxing Sun, Jie Sun
Rok vydání: 2021
Předmět:
Male
Chemistry
Pharmaceutical
Pharmaceutical Science
02 engineering and technology
Traditional Chinese medicine
030226 pharmacology & pharmacy
combination therapy
Mice
Random Allocation
Prostate cancer
0302 clinical medicine
Drug Stability
Prostate
polycyclic compounds
skin and connective tissue diseases
Drug Carriers
Mice
Inbred BALB C
education.field_of_study
integumentary system
tanshinone
General Medicine
Hydrogen-Ion Concentration
021001 nanoscience & nanotechnology
Lipids
Drug Combinations
medicine.anatomical_structure
Female
0210 nano-technology
Research Article
medicine.drug
Combination therapy
Cell Survival
Surface Properties
Population
Antineoplastic Agents
RM1-950
doxorubicin
03 medical and health sciences
Antigen
Cell Line
Tumor
medicine
Animals
Humans
Doxorubicin
Particle Size
education
business.industry
technology
industry
and agriculture
Prostatic Neoplasms
Cancer
pH-sensitive
medicine.disease
Xenograft Model Antitumor Assays
carbohydrates (lipids)
Drug Liberation
Abietanes
Cancer research
Nanoparticles
Therapeutics. Pharmacology
business
Zdroj: Drug Delivery
article-version (VoR) Version of Record
Drug Delivery, Vol 28, Iss 1, Pp 1132-1140 (2021)
ISSN: 1521-0464
1071-7544
DOI: 10.1080/10717544.2021.1931559
Popis: Prostate cancer is the second most frequently diagnosed cancer in the men population. Combination anticancer therapy using doxorubicin (DOX) and another extract of traditional Chinese medicine is one nano-sized drug delivery system promising to generate synergistic anticancer effects, maximize the treatment effect, and overcome multi-drug resistance. The purpose of this study is to construct a drug delivery system for the co-delivery of DOX and tanshinones (TAN). Lipid nanoparticles loaded with DOX and TAN (N-DOX/TAN) were prepared by emulsification and solvent-diffusion method. PSMA targeted nanoparticles loaded with DOX and TAN (P-N-DOX/TAN) were synthesized by conjugating a PSMA targeted ligand to N-DOX/TAN. We evaluate the performance of this system in vitro and in vivo. P-N-DOX/TAN has a size of 139.7 ± 4.1 nm and a zeta potential of 11.2 ± 1.6 mV. The drug release of DOX and TAN from P-N-DOX/TAN was much faster than that of N-DOX/TAN. N-DOX/TAN presented more inhibition effect on tumor growth than N-DOX and N-TAN, which is consistent with the synergistic results and successfully highlighting the advantages of combing the DOX and TAN in one system. P-N-DOX/TAN achieved higher uptake by LNCaP cells (58.9 ± 1.9%), highest tumor tissue distribution, and the most significant tumor inhibition efficiency. The novel nanomedicine offers great promise for the dual drug delivery to prostate cancer cells, showing the potential of synergistic combination therapy for prostate cancer.
Databáze: OpenAIRE
Externí odkaz: